Results 171 to 180 of about 3,235 (226)

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma. [PDF]

Cureus
Fujimoto M, Yanagihara T, Sakaki Y, Fujita M.   +3 more
europepmc   +1 more source

Tezepelumab in Patients With Severe Asthma: Response at 3 Months

Journal of Investigational Allergy and Clinical Immunology
J C, Miralles-López, R, Andújar-Espinosa, F J, Bravo-Gutierrez, S, Cabrejos-Perotti, M, Ramírez-Hernández, C, Díaz-Chantar, M J, Pajarón Fernández, J, Valverde-Molina, V, Pérez-Fernández   +8 more
openaire   +2 more sources

Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study. [PDF]

Respir Res
García-Rivero JL, Hannaoui Anaaoui A, Pallarés-Sanmartín A, Blanco-Aparicio M, García-Hernáez R, García-Gallardo Sanz V, Calvo-Álvarez U, Carazo-Fernández L, Hermida-Valverde T, Dorronsoro S, Carrascosa-Anguiano I, Lobato Astiárraga I, de Los Santos I, Enríquez-Rodríguez AI, Perez de Llano L, Álvarez Vega P, Abascal-Bolado B, Santibañez M.   +17 more
europepmc   +1 more source

A Narrative Review of Biologic Therapies for Type 2 Inflammation in Severe Asthma and Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): Mechanisms, Efficacy, and Safety. [PDF]

Cureus
Hemachandra S, Ngu JL, Goutama EN, Ooi HC, Angel A, Ei Cho T, Goh E, Aung AM, Inayah RS, Koo Kai Jie A, Gaur N.   +10 more
europepmc   +1 more source

Case Report: Tezepelumab as rescue therapy in near-fatal asthma requiring extracorporeal membrane oxygenation. [PDF]

Front Immunol
Oruqaj G, Bewersdorff J, Litzlbauer D, Wolff M, Sander M, Seeger W, Grimminger F, Hecker M, Tello K, Vadász I.   +9 more
europepmc   +1 more source

Real-World Effectiveness of Tezepelumab in Severe Asthma: A Comparative Analysis of High and Low T2 Phenotypes. [PDF]

J Pers Med
Chiner E, Boira I, Antón M, Bernabeu MÁ, Cuevas C, Fernández P, Esteban V, Llombart M.   +7 more
europepmc   +1 more source

COPD Biologics: Right Patient, Right Pathway, Right Time. [PDF]

Pulm Ther
Finney LJ, Conway FM, Sethi DK.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tezepelumab for asthma

Drugs of Today, 2022
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, namely interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), known as "alarmins".
Nolasco, Santi, Pelaia, Corrado, Scioscia, Giulia, Campisi, Raffaele, Crimi, Claudia   +4 more
openaire   +2 more sources

Tezepelumab in the Treatment of Uncontrolled Severe Asthma

Annals of Pharmacotherapy, 2022
Objective: To review the pharmacology, efficacy, and safety of subcutaneous tezepelumab in the treatment of severe uncontrolled asthma. Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms ...
Jacqueline Feist, Melissa Lipari, Pramodini Kale-Pradhan   +2 more
openaire   +2 more sources

Tezepelumab (Tezspire)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +1 more source